All Posts

My Take: A novel intervention that directly activates the enzyme deficitent in PKU Name: Sephience (sepiapterin) Class: Phenylalanine...

My Take: Oral delivery adds to treatment options, though price may become a limiting factor. Name: Ekterly ( sebetralstat ) Class: Oral...

My Take: An established pain med gains a new, useful route of administration Name:  Qdolo ( tramadol hydrochloride oral solution )...

My Take: A novel dual modality action, though cost may limit market penetration Name:  Inpefa ( sotagliflozin ) Class:  SGLT1 and...

My Take: A promising salvage ES-SCLC agent, though with an immunotherapy-average cost Name:  Tarlatamab-dlle (Brand name: Imdelltra)...

My Take: A vaccine that fills a niche need which may grow larger over time. Name:   Ixchiq (Live Attenuated Chikungunya Vaccine) Class: ...

My take: New hope for patients with a heritable, orphan illness Name: Garadacimab Class: Monoclonal Antibody (FXIIa inhibitor)...

My take: Effective, safe, and twice-per-year dosing, though cost may be the limiting factor Name: Lenacapavir Class: Capsid Inhibitor...

My Take: An overdue novel class of antibiotic for uncomplicated urinary tract infections Name: Blujepa (gepotidacin) Class: Antibiotic...

My Take: Good efficacy and fixed-dose (versus weight-based dosing) are both favorable Name: Enflonsia (clesrovimab‑cfor) Class: RSV F...